Abstract
Switch Therapeutics has launched with a $52 million series A. The California start-up aims to treat diseases by suppressing gene expression using cell-selective, noncoding double-stranded oligonucleotides known as small interfering RNA (siRNA) . Switch’s lead program is geared toward central nervous system conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
